My point, BTW, is: the average investor doesn't know how to interpret the results of clinical trials.
When a trial misses its primary endpoint and the company releases a PR bragging about the secondary endpoints or cherry-picking data, the average investor can be fooled into thinking the trial was a success.
That's my point.
The FDA, however, is never fooled by trials that miss their primary endpoints. Neither are you and I.
News 
Market Data 
Discover 
